What share of the U.S. antihypertensive market does amlodipine have?
The provided information does not include any market-share figures for amlodipine (for example, its share of the U.S. prescription antihypertensive market, or its share within specific classes like calcium-channel blockers). Without a defined source (such as IQVIA/IMS, Statista, NDC-based pharmacy datasets, or payer claims data), I can’t state an accurate number.
Which data sources are typically used for “amlodipine market share”?
If you’re trying to find the right benchmark, market share for a drug like amlodipine is usually reported using one of these approaches:
- Prescription volume share (units or scripts)
- Sales share (net sales revenue)
- Retail vs. total channel (retail, mail order, hospital)
- Specific geography (U.S., a country, or global)
- Specific denominator (all antihypertensives vs. just calcium-channel blockers vs. just branded drugs)
Different denominators can produce very different percentages, so it helps to specify what “market” means for your use case.
Market share in what sense—brand-only, generic-only, or total (branded + generic)?
Amlodipine is available as a generic and has multiple competitors, so “market share” can mean:
- Branded market share only (if tracked separately)
- Generic market share only
- Total market share across all products containing amlodipine
- Market share within the CCB class
To give the right figure, you need the exact definition and scope.
If you tell me the country and the market definition, I can point you to the right metric
Reply with:
1) Country (e.g., U.S.)
2) Denominator (all antihypertensives, or calcium-channel blockers, etc.)
3) Measure (scripts, units, or sales)
4) Timeframe (latest month, year, or a specific period)
Then I can help you locate the most relevant reported market-share number and interpret it correctly.